{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T01:12:24Z","timestamp":1790730744743,"version":"4.1.0"},"reference-count":151,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2019,10,9]],"date-time":"2019-10-09T00:00:00Z","timestamp":1570579200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"DOI":"10.3389\/fimmu.2019.02342","type":"journal-article","created":{"date-parts":[[2019,10,9]],"date-time":"2019-10-09T00:55:03Z","timestamp":1570582503000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":240,"title":["Targeting the Janus Kinase Family in Autoimmune Skin Diseases"],"prefix":"10.3389","volume":"10","author":[{"given":"Michael D.","family":"Howell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiona I.","family":"Kuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul A.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2019,10,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1038\/ni.3691","article-title":"Mechanisms and consequences of Jak-STAT signaling in the immune system","volume":"18","author":"Villarino","year":"2017","journal-title":"Nat Immunol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1242\/jcs.00963","article-title":"The JAK\/STAT signaling pathway","volume":"117","author":"Rawlings","year":"2004","journal-title":"J Cell Sci"},{"key":"B3","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.anai.2018.02.012","article-title":"JAK\/STAT inhibitors and other small molecule cytokine antagonists for the treatment of allergic disease","volume":"120","author":"Howell","year":"2018","journal-title":"Ann Allergy Asthma Immunol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"a028555","DOI":"10.1101\/cshperspect.a028555","article-title":"Responses to cytokines and interferons that depend upon JAKs and STATs","volume":"10","author":"Stark","year":"2018","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1084\/jem.20082900","article-title":"Control of T helper cell differentiation through cytokine receptor inclusion in the immunological synapse","volume":"206","author":"Maldonado","year":"2009","journal-title":"J Exp Med"},{"key":"B6","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1111\/j.0105-2896.2004.00209.x","article-title":"Signaling pathways in Th2 development","volume":"202","author":"Mowen","year":"2004","journal-title":"Immunol Rev"},{"key":"B7","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/j.smim.2007.10.015","article-title":"Signal transduction pathways and transcriptional regulation in the control of Th17 differentiation","volume":"19","author":"Chen","year":"2007","journal-title":"Semin Immunol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/j.micinf.2009.04.007","article-title":"Signal transduction and Th17 cell differentiation","volume":"11","author":"O'shea","year":"2009","journal-title":"Microbes Infect."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3109\/9780203908877-2","article-title":"The atopic eczema\/dermatitis syndrome. Epidemiology, natural course, and immunology of the IgE-associated (\u201cextrinsic\u201d) and the nonallergic (\u201cintrinsic\u201d)","volume":"13","author":"Wuthrich","year":"2003","journal-title":"AEDS J Investig Allergol Clin Immunol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"e39803","DOI":"10.1371\/journal.pone.0039803","article-title":"Investigating international time trends in the incidence and prevalence of atopic eczema 1990-2010: a systematic review of epidemiological studies","volume":"7","author":"Deckers","year":"2012","journal-title":"PLoS ONE."},{"key":"B11","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/j.jaci.2006.02.031","article-title":"Patient perspectives on the management of atopic dermatitis","volume":"118","author":"Zuberbier","year":"2006","journal-title":"J Allergy Clin Immunol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1111\/jdv.13599","article-title":"ETFAD\/EADV Eczema task force 2015 position paper on diagnosis and treatment of atopic dermatitis in adult and paediatric patients","volume":"30","author":"Wollenberg","year":"2016","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1111\/all.13231","article-title":"Atopic dermatitis is associated with anxiety, depression, and suicidal ideation, but not with psychiatric hospitalization or suicide","volume":"73","author":"Thyssen","year":"2018","journal-title":"Allergy"},{"key":"B14","doi-asserted-by":"publisher","first-page":"2177","DOI":"10.1080\/03007995.2018.1498329","article-title":"Patient impact and economic burden of mild-to-moderate atopic dermatitis","volume":"34","author":"Hebert","year":"2018","journal-title":"Curr Med Res Opin"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1016\/S0140-6736(15)00149-X","article-title":"Atopic dermatitis","volume":"387","author":"Weidinger","year":"2016","journal-title":"Lancet"},{"key":"B16","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1016\/j.jaci.2006.07.015","article-title":"Enhanced expression levels of IL-31 correlate with IL-4 and IL-13 in atopic and allergic contact dermatitis","volume":"118","author":"Neis","year":"2006","journal-title":"J Allergy Clin Immunol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/j.jdermsci.2016.09.007","article-title":"JAK inhibitor JTE-052 regulates contact hypersensitivity by downmodulating T cell activation and differentiation","volume":"84","author":"Amano","year":"2016","journal-title":"J Dermatol Sci"},{"key":"B18","doi-asserted-by":"publisher","first-page":"3973","DOI":"10.3390\/ijms19123973","article-title":"Topical application of JAK1\/JAK2 inhibitor momelotinib exhibits significant anti-inflammatory responses in DNCB-induced atopic dermatitis model mice","volume":"19","author":"Jin","year":"2018","journal-title":"Int J Mol Sci"},{"key":"B19","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1124\/jpet.115.223784","article-title":"Topically administered janus-kinase inhibitors tofacitinib and oclacitinib display impressive antipruritic and anti-inflammatory responses in a model of allergic dermatitis","volume":"354","author":"Fukuyama","year":"2015","journal-title":"J Pharmacol Exp Ther"},{"key":"B20","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1159\/000347184","article-title":"Effects of the Janus kinase inhibitor CP-690550 (tofacitinib) in a rat model of oxazolone-induced chronic dermatitis","volume":"91","author":"Fujii","year":"2013","journal-title":"Pharmacology"},{"key":"B21","doi-asserted-by":"publisher","first-page":"3695","DOI":"10.4049\/jimmunol.174.6.3695","article-title":"IL-22 inhibits epidermal differentiation and induces proinflammatory gene expression and migration of human keratinocytes","volume":"174","author":"Boniface","year":"2005","journal-title":"J Immunol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"2543","DOI":"10.4049\/jimmunol.1600126","article-title":"Expression of IL-22 in the Skin Causes Th2-Biased Immunity, Epidermal Barrier Dysfunction, and Pruritus via Stimulating Epithelial Th2 Cytokines and the GRP Pathway","volume":"198","author":"Lou","year":"2017","journal-title":"J Immunol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1016\/j.jaad.2018.01.016","article-title":"Efficacy and safety of fezakinumab (an IL-22 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by conventional treatments: a randomized, double-blind, phase 2a trial","volume":"78","author":"Guttman-Yassky","year":"2018","journal-title":"J Am Acad Dermatol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"33676","DOI":"10.1074\/jbc.M204204200","article-title":"Interleukin-22 (IL-22) activates the JAK\/STAT, ERK, JNK, and p38 MAP kinase pathways in a rat hepatoma cell line. Pathways that are shared with and distinct from IL-10","volume":"277","author":"Lejeune","year":"2002","journal-title":"J Biol Chem."},{"key":"B25","doi-asserted-by":"publisher","first-page":"E3086","DOI":"10.3390\/ijms19103086","article-title":"New cytokines in the pathogenesis of atopic dermatitis-new therapeutic targets","volume":"19","author":"Klonowska","year":"2018","journal-title":"Int J Mol Sci"},{"key":"B26","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.cytogfr.2008.08.003","article-title":"Structures and biological functions of IL-31 and IL-31 receptors","volume":"19","author":"Zhang","year":"2008","journal-title":"Cytokine Growth Factor Rev"},{"key":"B27","doi-asserted-by":"publisher","first-page":"bau007","DOI":"10.1093\/database\/bau007","article-title":"TSLP signaling pathway map: a platform for analysis of TSLP-mediated signaling","volume":"2014","author":"Zhong","year":"2014","journal-title":"Database."},{"key":"B28","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1111\/jvp.12101","article-title":"Oclacitinib (APOQUEL\u00ae) is a novel Janus kinase inhibitor with activity against cytokines involved in allergy","volume":"37","author":"Gonzales","year":"2014","journal-title":"J Vet Pharmacol Ther"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1838","DOI":"10.1038\/jid.2011.140","article-title":"Preclinical evaluation of local JAK1 and JAK2 inhibition in cutaneous inflammation","volume":"131","author":"Fridman","year":"2011","journal-title":"J Invest Dermatol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1038\/jid.2012.239","article-title":"TSLP produced by keratinocytes promotes allergen sensitization through skin and thereby triggers atopic march in mice","volume":"133","author":"Leyva-Castillo","year":"2013","journal-title":"J Invest Dermatol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.cell.2017.08.006","article-title":"Sensory neurons co-opt classical immune signaling pathways to mediate chronic itch","volume":"171","author":"Oetjen","year":"2017","journal-title":"Cell."},{"key":"B32","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1016\/j.clim.2007.11.006","article-title":"Loricrin and involucrin expression is down-regulated by Th2 cytokines through STAT-6","volume":"126","author":"Kim","year":"2008","journal-title":"Clin Immunol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"984","DOI":"10.4049\/jimmunol.179.2.984","article-title":"IL-4 and IL-13 negatively regulate TNF-alpha- and IFN-gamma-induced beta-defensin expression through STAT-6, suppressor of cytokine signaling (SOCS)-1, and SOCS-3","volume":"179","author":"Albanesi","year":"2007","journal-title":"J Immunol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"3186","DOI":"10.4049\/jimmunol.0901860","article-title":"IL-4 regulates skin homeostasis and the predisposition toward allergic skin inflammation","volume":"184","author":"Sehra","year":"2010","journal-title":"J Immunol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"2064","DOI":"10.1172\/JCI82887","article-title":"Hyperactivation of JAK1 tyrosine kinase induces stepwise, progressive pruritic dermatitis","volume":"126","author":"Yasuda","year":"2016","journal-title":"J Clin Invest"},{"key":"B36","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1016\/j.jaci.2015.03.051","article-title":"The Janus kinase inhibitor JTE-052 improves skin barrier function through suppressing signal transducer and activator of transcription 3 signaling","volume":"136","author":"Amano","year":"2015","journal-title":"J Allergy Clin Immunol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"2114","DOI":"10.1038\/jid.2014.43","article-title":"Th2 cytokines increase Staphylococcus aureus alpha toxin-induced keratinocyte death through the signal transducer and activator of transcription 6 (STAT6)","volume":"134","author":"Brauweiler","year":"2014","journal-title":"J Invest Dermatol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"2625","DOI":"10.1038\/jid.2008.111","article-title":"Possible pathogenic role of Th17 cells for atopic dermatitis","volume":"128","author":"Koga","year":"2008","journal-title":"J Invest Dermatol"},{"key":"B39","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1016\/j.jaci.2015.08.015","article-title":"The Asian atopic dermatitis phenotype combines features of atopic dermatitis and psoriasis with increased TH17 polarization","volume":"136","author":"Noda","year":"2015","journal-title":"J Allergy Clin Immunol"},{"key":"B40","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/j.jaad.2015.06.045","article-title":"Treatment of recalcitrant atopic dermatitis with the oral Janus kinase inhibitor tofacitinib citrate","volume":"73","author":"Levy","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"B41","article-title":"Primary results from a phase 2b, randomized, placebo-controlled trial of upadacitinib for patients with atopic dermatitis","volume-title":"Presented at: The American Academy of Dermatology (AAD) Annual Meeting, February 16-20","author":"Guttman-Yassky","year":"2018"},{"key":"B42","article-title":"Efficacy and safety of baricitinib in moderate to severe atopic dermatitis: results of two phase 3 monotherapy randomized, double-blind, placebo-controlled 16-week trials (BREEZE-AD1 and BREEZA-AD2)","volume-title":"Presented at: The 24th World Congress of Dermatology (WCD).","author":"Simpson","year":"2019"},{"key":"B43","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1111\/bjd.14871","article-title":"Topical tofacitinib for atopic dermatitis: a phase IIa randomized trial","volume":"175","author":"Bissonnette","year":"2016","journal-title":"Br J Dermatol"},{"key":"B44","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1016\/j.jaci.2015.12.1318","article-title":"Tofacitinib attenuates pathologic immune pathways in patients with psoriasis: a randomized phase 2 study","volume":"137","author":"Krueger","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"B45","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.jdermsci.2017.05.004","article-title":"The efficacy and safety of tofacitinib in Asian patients with moderate to severe chronic plaque psoriasis: a Phase 3, randomized, double-blind, placebo-controlled study","volume":"88","author":"Zhang","year":"2017","journal-title":"J Dermatol Sci"},{"key":"B46","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.jaad.2017.01.053","article-title":"Efficacy of tofacitinib for the treatment of nail psoriasis: two 52-week, randomized, controlled phase 3 studies in patients with moderate-to-severe plaque psoriasis","volume":"77","author":"Merola","year":"2017","journal-title":"J Am Acad Dermatol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1016\/S0140-6736(14)62113-9","article-title":"Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial","volume":"386","author":"Bachelez","year":"2015","journal-title":"Lancet"},{"key":"B48","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1111\/bjd.13551","article-title":"Tofacitinib withdrawal and retreatment in moderate-to-severe chronic plaque psoriasis: a randomized controlled trial","volume":"172","author":"Bissonnette","year":"2015","journal-title":"Br J Dermatol"},{"key":"B49","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1111\/bjd.16798","article-title":"Tofacitinib in patients with moderate-to-severe chronic plaque psoriasis: long-term safety and efficacy in an open-label extension study","volume":"179","author":"Valenzuela","year":"2018","journal-title":"Br J Dermatol"},{"key":"B50","doi-asserted-by":"publisher","first-page":"e89776","DOI":"10.1172\/jci.insight.89776","article-title":"Safety and efficacy of the JAK inhibitor tofacitinib citrate in patients with alopecia areata","volume":"1","author":"Kennedy Crispin","year":"2016","journal-title":"JCI Insight"},{"key":"B51","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1111\/bjd.16004","article-title":"Efficacy and safety of the Janus kinase 1 inhibitor PF-04965842 in patients with moderate-to-severe psoriasis: phase II, randomized, double-blind, placebo-controlled study","volume":"179","author":"Schmieder","year":"2018","journal-title":"Br J Dermatol"},{"key":"B52","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1111\/bjd.14403","article-title":"A randomized phase 2b trial of baricitinib, an oral Janus kinase (JAK) 1\/JAK2 inhibitor, in patients with moderate-to-severe psoriasis","volume":"174","author":"Papp","year":"2016","journal-title":"Br J Dermatol"},{"key":"B53","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1016\/j.jaad.2018.01.018","article-title":"Baricitinib in adult patients with moderate-to-severe atopic dermatitis: a phase 2 parallel, double-blinded, randomized placebo-controlled multiple-dose study","volume":"80","author":"Guttman-Yassky","year":"2019","journal-title":"J Am Acad Dermatol."},{"key":"B54","doi-asserted-by":"publisher","first-page":"e89790","DOI":"10.1172\/jci.insight.89790","article-title":"Oral ruxolitinib induces hair regrowth in patients with moderate-to-severe alopecia areata","volume":"1","author":"Mackay-Wiggan","year":"2016","journal-title":"JCI Insight"},{"key":"B55","doi-asserted-by":"publisher","first-page":"332","DOI":"10.3109\/09546634.2015.1115819","article-title":"A randomized, double-blind, placebo-controlled, dose-escalation study of the safety and efficacy of INCB039110, an oral janus kinase 1 inhibitor, in patients with stable, chronic plaque psoriasis","volume":"27","author":"Bissonnette","year":"2016","journal-title":"J Dermatolog Treat."},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.17932","article-title":"The oral Janus kinase\/spleen tyrosine kinase inhibitor ASN002 demonstrates efficacy and improves associated systemic inflammation in patients with moderate-to-severe atopic dermatitis: results from a randomized double-blind placebo-controlled study","author":"Bissonnette","year":"2019","journal-title":"Br J Dermatol"},{"key":"B57","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1056\/NEJMoa1806382","article-title":"Phase 2 trial of selective tyrosine Kinase 2 inhibition in psoriasis","volume":"379","author":"Papp","year":"2018","journal-title":"N Engl J Med"},{"key":"B58","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1111\/bjd.13745","article-title":"A phase 2a randomized, double-blind, placebo-controlled, sequential dose-escalation study to evaluate the efficacy and safety of ASP015K, a novel Janus kinase inhibitor, in patients with moderate-to-severe psoriasis","volume":"173","author":"Papp","year":"2015","journal-title":"Br J Dermatol"},{"key":"B59","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s12895-016-0051-4","article-title":"Treatment of plaque psoriasis with an ointment formulation of the Janus kinase inhibitor, tofacitinib: a Phase 2b randomized clinical trial","volume":"16","author":"Papp","year":"2016","journal-title":"BMC Dermatol."},{"key":"B60","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1111\/bjd.12266","article-title":"A randomized phase 2a efficacy and safety trial of the topical Janus kinase inhibitor tofacitinib in the treatment of chronic plaque psoriasis","volume":"169","author":"Ports","year":"2013","journal-title":"Br J Dermatol"},{"key":"B61","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.jaad.2017.10.043","article-title":"Tofacitinib 2% ointment, a topical Janus kinase inhibitor, for the treatment of alopecia areata: a pilot study of 10 patients","volume":"78","author":"Liu","year":"2018","journal-title":"J Am Acad Dermatol."},{"key":"B62","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1016\/j.jaad.2011.12.018","article-title":"Preliminary clinical activity of a topical JAK1\/2 inhibitor in the treatment of psoriasis","volume":"67","author":"Punwani","year":"2012","journal-title":"J Am Acad Dermatol"},{"key":"B63","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1111\/bjd.13994","article-title":"Downmodulation of key inflammatory cell markers with a topical Janus kinase 1\/2 inhibitor","volume":"173","author":"Punwani","year":"2015","journal-title":"Br J Dermatol"},{"key":"B64","article-title":"A phase 2, randomized, dose-ranging, vehicle- and active-controlled study to evaluate the safety and efficacy of topical ruxolitinib in adult patients with atopic dermatitis","volume-title":"Presented at: The 27th European Academy of Dermatology and Venereology (EADV) Congress.","author":"Kim","year":"2018"},{"key":"B65","article-title":"12-Week efficacy and safety data of ruxolitinib cream in adult patients with atopic dermatitis: results from a phase 2 study","volume-title":"Presented at: The 24th World Congress of Dermatology (WCD).","author":"Raoof","year":"2019"},{"key":"B66","article-title":"Efficacy and safety of ruxolitinib cream for the treatment of Vitiligo: results of a 24-week randomized, double-blind, dose-ranging, vehicle-controlled study","volume-title":"Presented at the 24th World Congress of Dermatology.","author":"Rosmarin","year":"2019"},{"key":"B67","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1016\/j.jaad.2017.02.049","article-title":"Treatment of vitiligo with the topical Janus kinase inhibitor ruxolitinib","volume":"76","author":"Rothstein","year":"2017","journal-title":"J Am Acad Dermatol."},{"key":"B68","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jaad.2017.04.1141","article-title":"Alopecia areata: Disease characteristics, clinical evaluation, and new perspectives on pathogenesis","volume":"78","author":"Strazzulla","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"B69","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.it.2004.09.014","article-title":"A 'hairy' privilege","volume":"26","author":"Paus","year":"2005","journal-title":"Trends Immunol"},{"key":"B70","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1056\/NEJMra1103442","article-title":"Alopecia areata","volume":"366","author":"Gilhar","year":"2012","journal-title":"N Engl J Med"},{"key":"B71","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1111\/exd.12209","article-title":"What causes alopecia areata?","volume":"22","author":"Mcelwee","year":"2013","journal-title":"Exp Dermatol"},{"key":"B72","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1586\/1744666X.2015.1085306","article-title":"The role of lymphocytes in the development and treatment of alopecia areata","volume":"11","author":"Guo","year":"2015","journal-title":"Expert Rev Clin Immunol"},{"key":"B73","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1038\/sj.jidsp.5640217","article-title":"Immunology of the hair follicle: a short journey into terra incognita","volume":"4","author":"Paus","year":"1999","journal-title":"J Investig Dermatol Symp Proc"},{"key":"B74","doi-asserted-by":"publisher","first-page":"2677","DOI":"10.1038\/jid.2010.180","article-title":"Hair follicles from alopecia areata patients exhibit alterations in immune privilege-associated gene expression in advance of hair loss","volume":"130","author":"Kang","year":"2010","journal-title":"J Invest Dermatol"},{"key":"B75","doi-asserted-by":"publisher","first-page":"1722","DOI":"10.1038\/jid.2013.53","article-title":"Somatostatin expression in human hair follicles and its potential role in immune privilege","volume":"133","author":"Breitkopf","year":"2013","journal-title":"J Invest Dermatol"},{"key":"B76","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1038\/jid.2013.368","article-title":"Hair follicle mesenchyme-associated PD-L1 regulates T-cell activation induced apoptosis: a potential mechanism of immune privilege","volume":"134","author":"Wang","year":"2014","journal-title":"J Invest Dermatol"},{"key":"B77","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1046\/j.1523-1747.1998.00380.x","article-title":"Experimental induction of alopecia areata-like hair loss in C3H\/HeJ mice using full-thickness skin grafts","volume":"111","author":"Mcelwee","year":"1998","journal-title":"J Invest Dermatol."},{"key":"B78","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1159\/000028002","article-title":"Comparison of alopecia areata in human and nonhuman mammalian species","volume":"66","author":"Mcelwee","year":"1998","journal-title":"Pathobiology."},{"key":"B79","doi-asserted-by":"publisher","first-page":"12518","DOI":"10.1038\/s41598-018-30997-3","article-title":"Induction of alopecia areata in C3H\/HeJ mice using polyinosinic-polycytidylic acid (poly[I:C]) and interferon-gamma","volume":"8","author":"Shin","year":"2018","journal-title":"Sci Rep"},{"key":"B80","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.ebiom.2015.02.015","article-title":"Reversal of alopecia areata following treatment with the JAK1\/2 inhibitor baricitinib","volume":"2","author":"Jabbari","year":"2015","journal-title":"EBioMedicine"},{"key":"B81","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1038\/nm.3645","article-title":"Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition","volume":"20","author":"Xing","year":"2014","journal-title":"Nat Med"},{"key":"B82","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1111\/j.1365-2133.2010.09775.x","article-title":"Type 1 interferon signature in the scalp lesions of alopecia areata","volume":"163","author":"Ghoreishi","year":"2010","journal-title":"Br J Dermatol"},{"key":"B83","doi-asserted-by":"publisher","first-page":"121949","DOI":"10.1172\/jci.insight.121949","article-title":"High-throughput T cell receptor sequencing identifies clonally expanded CD8+ T cell populations in alopecia areata","volume":"3","author":"De Jong","year":"2018","journal-title":"JCI Insight"},{"key":"B84","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1111\/exd.12918","article-title":"Biomarkers of alopecia areata disease activity and response to corticosteroid treatment","volume":"25","author":"Fuentes-Duculan","year":"2016","journal-title":"Exp Dermatol"},{"key":"B85","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1111\/j.1365-2133.2006.07377.x","article-title":"Interferon-gamma-deficient mice are resistant to the development of alopecia areata","volume":"155","author":"Freyschmidt-Paul","year":"2006","journal-title":"Br J Dermatol"},{"key":"B86","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1016\/S0002-9440(10)63151-3","article-title":"Collapse and restoration of MHC class-I-dependent immune privilege: exploiting the human hair follicle as a model","volume":"164","author":"Ito","year":"2004","journal-title":"Am J Pathol"},{"key":"B87","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1038\/nature09114","article-title":"Genome-wide association study in alopecia areata implicates both innate and adaptive immunity","volume":"466","author":"Petukhova","year":"2010","journal-title":"Nature"},{"key":"B88","doi-asserted-by":"publisher","first-page":"17011","DOI":"10.1038\/nrdp.2017.11","article-title":"Alopecia areata","volume":"3","author":"Pratt","year":"2017","journal-title":"Nat Rev Dis Primers"},{"key":"B89","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1111\/jdv.12932","article-title":"Plasmacytoid dendritic cells in alopecia areata: missing link?","volume":"30","author":"Abou Rahal","year":"2016","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B90","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1684\/ejd.2010.0816","article-title":"Plasmacytoid dendritic cells and dermatological disorders: focus on their role in autoimmunity and cancer","volume":"20","author":"Charles","year":"2010","journal-title":"Eur J Dermatol"},{"key":"B91","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1038\/jid.2012.17","article-title":"Increased expression of Cxcr3 and its ligands, Cxcl9 and Cxcl10, during the development of alopecia areata in the mouse","volume":"132","author":"Mcphee","year":"2012","journal-title":"J Invest Dermatol"},{"key":"B92","doi-asserted-by":"publisher","first-page":"271","DOI":"10.3389\/fmed.2018.00271","article-title":"The role of CXCR3 and its chemokine ligands in skin disease and cancer","volume":"5","author":"Kuo","year":"2018","journal-title":"Front Med"},{"key":"B93","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1038\/nri3919","article-title":"IL-15 functions as a danger signal to regulate tissue-resident T cells and tissue destruction","volume":"15","author":"Jabri","year":"2015","journal-title":"Nat Rev Immunol"},{"key":"B94","doi-asserted-by":"publisher","first-page":"15722","DOI":"10.1038\/srep15722","article-title":"Trans-presentation of IL-15 modulates STAT5 activation and Bcl-6 expression in TH1 cells","volume":"5","author":"Cooley","year":"2015","journal-title":"Sci Rep"},{"key":"B95","doi-asserted-by":"publisher","first-page":"5966","DOI":"10.1038\/ncomms6966","article-title":"Genome-wide meta-analysis in alopecia areata resolves HLA associations and reveals two new susceptibility loci","volume":"6","author":"Betz","year":"2015","journal-title":"Nat Commun"},{"key":"B96","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1016\/j.immuni.2012.03.014","article-title":"JAK and STAT signaling molecules in immunoregulation and immune-mediated disease","volume":"36","author":"O'shea","year":"2012","journal-title":"Immunity."},{"key":"B97","doi-asserted-by":"publisher","first-page":"e1500973","DOI":"10.1126\/sciadv.1500973","article-title":"Pharmacologic inhibition of JAK-STAT signaling promotes hair growth","volume":"1","author":"Harel","year":"2015","journal-title":"Sci Adv"},{"key":"B98","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1007\/s00403-017-1777-5","article-title":"Efficacy of topical tofacitinib in promoting hair growth in non-scarring alopecia: possible mechanism via VEGF induction","volume":"309","author":"Meephansan","year":"2017","journal-title":"Arch Dermatol Res"},{"key":"B99","doi-asserted-by":"publisher","first-page":"2988","DOI":"10.1038\/jid.2014.260","article-title":"Killing two birds with one stone: oral tofacitinib reverses alopecia universalis in a patient with plaque psoriasis","volume":"134","author":"Craiglow","year":"2014","journal-title":"J Invest Dermatol"},{"key":"B100","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1016\/j.jaci.2014.12.1867","article-title":"Use of ruxolitinib to successfully treat chronic mucocutaneous candidiasis caused by gain-of-function signal transducer and activator of transcription 1 (STAT1) mutation","volume":"135","author":"Higgins","year":"2015","journal-title":"J Allergy Clin Immunol"},{"key":"B101","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1002\/ajh.23871","article-title":"Ruxolitinib-induced reversal of alopecia universalis in a patient with essential thrombocythemia","volume":"90","author":"Pieri","year":"2015","journal-title":"Am J Hematol"},{"key":"B102","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.jaad.2015.09.073","article-title":"Rapid skin repigmentation on oral ruxolitinib in a patient with coexistent vitiligo and alopecia areata (AA)","volume":"74","author":"Harris","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"B103","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s12969-019-0322-9","article-title":"Disease course and treatment effects of a JAK inhibitor in a patient with CANDLE syndrome","volume":"17","author":"Boyadzhiev","year":"2019","journal-title":"Pediatr Rheumatol Online J"},{"key":"B104","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1016\/j.jid.2018.01.032","article-title":"An Open-Label Pilot Study to Evaluate the Efficacy of Tofacitinib in Moderate to Severe Patch-Type Alopecia Areata, Totalis, and Universalis","volume":"138","author":"Jabbari","year":"2018","journal-title":"J Invest Dermatol"},{"key":"B105","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.jaad.2016.09.006","article-title":"Tofacitinib for the treatment of alopecia areata and variants in adolescents","volume":"76","author":"Craiglow","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"B106","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.jaad.2016.09.007","article-title":"Tofacitinib for the treatment of severe alopecia areata and variants: a study of 90 patients","volume":"76","author":"Liu","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"B107","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1016\/j.jaad.2017.05.043","article-title":"Repigmentation in vitiligo using the Janus kinase inhibitor tofacitinib may require concomitant light exposure","volume":"77","author":"Liu","year":"2017","journal-title":"J Am Acad Dermatol."},{"key":"B108","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1001\/jamadermatol.2015.1520","article-title":"Tofacitinib citrate for the treatment of vitiligo: a pathogenesis-directed therapy","volume":"151","author":"Craiglow","year":"2015","journal-title":"JAMA Dermatol"},{"key":"B109","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.jaad.2017.03.024","article-title":"Topical Janus kinase inhibitors for the treatment of pediatric alopecia areata","volume":"77","author":"Bayart","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"B110","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1056\/NEJMra0804595","article-title":"Psoriasis","volume":"361","author":"Nestle","year":"2009","journal-title":"N Engl J Med"},{"key":"B111","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1111\/j.1365-2249.2007.03356.x","article-title":"The role of T helper 17 (Th17) and regulatory T cells (Treg) in human organ transplantation and autoimmune disease","volume":"148","author":"Afzali","year":"2007","journal-title":"Clin Exp Immunol"},{"key":"B112","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/j.clindermatol.2007.08.013","article-title":"Resident skin cells in psoriasis: a special look at the pathogenetic functions of keratinocytes","volume":"25","author":"Albanesi","year":"2007","journal-title":"Clin Dermatol."},{"key":"B113","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1084\/jem.20030451","article-title":"Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris","volume":"199","author":"Lee","year":"2004","journal-title":"J Exp Med"},{"key":"B114","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.immuni.2009.08.001","article-title":"Interleukin-1 and IL-23 induce innate IL-17 production from gammadelta T cells, amplifying Th17 responses and autoimmunity","volume":"31","author":"Sutton","year":"2009","journal-title":"Immunity"},{"key":"B115","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1038\/nature05505","article-title":"Interleukin-22, a T(H)17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis","volume":"445","author":"Zheng","year":"2007","journal-title":"Nature"},{"key":"B116","doi-asserted-by":"publisher","first-page":"E530","DOI":"10.3390\/ijms19020530","article-title":"Role of the IL-23\/IL-17 axis in psoriasis and psoriatic arthritis: the clinical importance of its divergence in skin and joints","volume":"19","author":"Boutet","year":"2018","journal-title":"Int J Mol Sci"},{"key":"B117","doi-asserted-by":"publisher","first-page":"4","DOI":"10.12703\/P6-4","article-title":"Advances in treating psoriasis","volume":"6","author":"Belge","year":"2014","journal-title":"F1000Prime Rep."},{"key":"B118","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s00403-017-1792-6","article-title":"Expression of Janus Kinase 1 in vitiligo and psoriasis before and after narrow band UVB: a case-control study","volume":"310","author":"Nada","year":"2018","journal-title":"Arch Dermatol Res"},{"key":"B119","doi-asserted-by":"publisher","first-page":"34605","DOI":"10.1074\/jbc.M705100200","article-title":"IL-21 is produced by Th17 cells and drives IL-17 production in a STAT3-dependent manner","volume":"282","author":"Wei","year":"2007","journal-title":"J Biol Chem."},{"key":"B120","doi-asserted-by":"publisher","first-page":"2306","DOI":"10.2741\/4054","article-title":"IL-6, IL-17 and STAT3: a holy trinity in auto-immunity?","volume":"17","author":"Camporeale","year":"2012","journal-title":"Front Biosci"},{"key":"B121","doi-asserted-by":"publisher","first-page":"5836","DOI":"10.4049\/jimmunol.0802999","article-title":"Imiquimod-induced psoriasis-like skin inflammation in mice is mediated via the IL-23\/IL-17 axis","volume":"182","author":"Van Der Fits","year":"2009","journal-title":"J Immunol"},{"key":"B122","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1111\/exd.13370","article-title":"A novel JAK inhibitor JTE-052 reduces skin inflammation and ameliorates chronic dermatitis in rodent models: comparison with conventional therapeutic agents","volume":"27","author":"Tanimoto","year":"2018","journal-title":"Exp Dermatol"},{"key":"B123","doi-asserted-by":"publisher","first-page":"4234","DOI":"10.4049\/jimmunol.1003668","article-title":"Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550)","volume":"186","author":"Ghoreschi","year":"2011","journal-title":"J Immunol"},{"key":"B124","doi-asserted-by":"publisher","first-page":"7897263","DOI":"10.1155\/2018\/7897263","article-title":"Selective immunomodulation of inflammatory pathways in keratinocytes by the Janus Kinase (JAK) inhibitor tofacitinib: implications for the employment of JAK-targeting drugs in psoriasis","volume":"2018","author":"Morelli","year":"2018","journal-title":"J Immunol Res"},{"key":"B125","doi-asserted-by":"publisher","first-page":"2183","DOI":"10.4049\/jimmunol.0804063","article-title":"JAK3 inhibition significantly attenuates psoriasiform skin inflammation in CD18 mutant PL\/J mice","volume":"183","author":"Chang","year":"2009","journal-title":"J Immunol"},{"key":"B126","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/S1074-7613(00)00054-6","article-title":"Partial impairment of cytokine responses in Tyk2-deficient mice","volume":"13","author":"Karaghiosoff","year":"2000","journal-title":"Immunity"},{"key":"B127","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1016\/S1074-7613(00)00055-8","article-title":"Tyk2 plays a restricted role in IFN alpha signaling, although it is required for IL-12-mediated T cell function","volume":"13","author":"Shimoda","year":"2000","journal-title":"Immunity"},{"key":"B128","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1093\/intimm\/dxt062","article-title":"Tyk2 is a therapeutic target for psoriasis-like skin inflammation","volume":"26","author":"Ishizaki","year":"2014","journal-title":"Int Immunol"},{"key":"B129","doi-asserted-by":"publisher","first-page":"3278","DOI":"10.4049\/jimmunol.1400205","article-title":"Inhibition of TYK2 and JAK1 ameliorates imiquimod-induced psoriasis-like dermatitis by inhibiting IL-22 and the IL-23\/IL-17 axis","volume":"193","author":"Works","year":"2014","journal-title":"J Immunol"},{"key":"B130","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1038\/nm1162","article-title":"Stat3 links activated keratinocytes and immunocytes required for development of psoriasis in a novel transgenic mouse model","volume":"11","author":"Sano","year":"2005","journal-title":"Nat Med"},{"key":"B131","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1038\/jid.2010.255","article-title":"Stat3 as a therapeutic target for the treatment of psoriasis: a clinical feasibility study with STA-21, a Stat3 inhibitor","volume":"131","author":"Miyoshi","year":"2011","journal-title":"J Invest Dermatol"},{"key":"B132","doi-asserted-by":"publisher","first-page":"4481","DOI":"10.4049\/jimmunol.1000148","article-title":"Distinct roles of IL-23 and IL-17 in the development of psoriasis-like lesions in a mouse model","volume":"186","author":"Nakajima","year":"2011","journal-title":"J Immunol"},{"key":"B133","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1111\/bjd.14399","article-title":"Investigation of selective JAK1 inhibitor GSK2586184 for the treatment of psoriasis in a randomized placebo-controlled phase IIa study","volume":"174","author":"Ludbrook","year":"2016","journal-title":"Br J Dermatol"},{"key":"B134","first-page":"777","article-title":"Randomized pilot clinical trial of tofacitinib solution for plaque psoriasis: challenges of the intra-subject study design","volume":"14","author":"Ports","year":"2015","journal-title":"J Drugs Dermatol"},{"key":"B135","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1111\/j.1365-4632.2011.05377.x","article-title":"A review of the worldwide prevalence of vitiligo in children\/adolescents and adults","volume":"51","author":"Kruger","year":"2012","journal-title":"Int J Dermatol"},{"key":"B136","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1007\/s12016-017-8622-7","article-title":"Vitiligo: focus on clinical aspects, immunopathogenesis, and therapy","volume":"54","author":"Boniface","year":"2018","journal-title":"Clin Rev Allergy Immunol"},{"key":"B137","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1111\/j.1365-2133.2009.09091.x","article-title":"Willingness-to-pay and quality of life in patients with vitiligo","volume":"161","author":"Radtke","year":"2009","journal-title":"Br J Dermatol"},{"key":"B138","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1111\/j.1365-2230.2009.03765.x","article-title":"Vitiligo is more than skin deep: a survey of members of the Vitiligo Society","volume":"35","author":"Talsania","year":"2010","journal-title":"Clin Exp Dermatol"},{"key":"B139","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1084\/jem.188.6.1203","article-title":"High frequency of skin-homing melanocyte-specific cytotoxic T lymphocytes in autoimmune vitiligo","volume":"188","author":"Ogg","year":"1998","journal-title":"J Exp Med"},{"key":"B140","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1038\/jid.2009.32","article-title":"Autoimmune destruction of skin melanocytes by perilesional T cells from vitiligo patients","volume":"129","author":"Van Den Boorn","year":"2009","journal-title":"J Invest Dermatol"},{"key":"B141","doi-asserted-by":"publisher","first-page":"223ra223","DOI":"10.1126\/scitranslmed.3007811","article-title":"CXCL10 is critical for the progression and maintenance of depigmentation in a mouse model of vitiligo","volume":"6","author":"Rashighi","year":"2014","journal-title":"Sci Transl Med."},{"key":"B142","doi-asserted-by":"publisher","first-page":"3105","DOI":"10.1038\/jid.2015.335","article-title":"Transcriptional analysis of vitiligo skin reveals the alteration of WNT pathway: a promising target for repigmenting vitiligo patients","volume":"135","author":"Regazzetti","year":"2015","journal-title":"J Invest Dermatol"},{"key":"B143","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1111\/pcmr.12667","article-title":"CXCL-10 and Interleukin-6 are reliable serum markers for vitiligo activity: a multicenter cross-sectional study","volume":"31","author":"Abdallah","year":"2018","journal-title":"Pigment Cell Melanoma Res"},{"key":"B144","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1016\/j.jaad.2016.12.021","article-title":"Suction blistering the lesional skin of vitiligo patients reveals useful biomarkers of disease activity","volume":"76","author":"Strassner","year":"2017","journal-title":"J Am Acad Dermatol."},{"key":"B145","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1016\/j.jid.2016.10.048","article-title":"CXCR3 depleting antibodies prevent and reverse vitiligo in mice","volume":"137","author":"Richmond","year":"2017","journal-title":"J Invest Dermatol."},{"key":"B146","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1016\/j.jid.2016.09.016","article-title":"Keratinocyte-derived chemokines orchestrate T-cell positioning in the epidermis during vitiligo and may serve as biomarkers of disease","volume":"137","author":"Richmond","year":"2017","journal-title":"J Invest Dermatol."},{"key":"B147","doi-asserted-by":"publisher","first-page":"363","DOI":"10.4132\/jptm.2018.09.18","article-title":"Immunohistochemistry of Janus Kinase 1 (JAK1) Expression in Vitiligo","volume":"52","author":"Abdou","year":"2018","journal-title":"J Pathol Transl Med"},{"key":"B148","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1177\/1203475419833609","article-title":"The use of janus kinase inhibitors in Vitiligo: a review of the literature","volume":"23","author":"Relke","year":"2019","journal-title":"J Cutan Med Surg"},{"key":"B149","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1001\/jamadermatol.2017.5778","article-title":"Rapid repigmentation of vitiligo using tofacitinib plus low-dose, narrowband UV-B phototherapy","volume":"154","author":"Kim","year":"2018","journal-title":"JAMA Dermatol."},{"key":"B150","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1093\/rheumatology\/key339","article-title":"Clinical significance of Janus Kinase inhibitor selectivity","volume":"58","author":"Choy","year":"2019","journal-title":"Rheumatology."},{"key":"B151","doi-asserted-by":"publisher","first-page":"i43","DOI":"10.1093\/rheumatology\/key276","article-title":"JAK-inhibitors. New players in the field of immune-mediated diseases, beyond rheumatoid arthritis","volume":"58","author":"Fragoulis","year":"2019","journal-title":"Rheumatology."}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2019.02342\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,9]],"date-time":"2019-10-09T00:55:07Z","timestamp":1570582507000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2019.02342\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,9]]},"references-count":151,"alternative-id":["10.3389\/fimmu.2019.02342"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2019.02342","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,9]]},"article-number":"2342"}}